Long-term chemotherapy-related cardiovascular morbidity

被引:84
作者
Meinardi, MT
Gietema, JA
van Veldhuisen, DJ
van der Graaf, WTA
de Vries, EGE
Sleijfer, DT
机构
[1] Univ Groningen Hosp, Dept Internal Med, Div Med Oncol, NL-9700 RB Groningen, Netherlands
[2] Univ Groningen Hosp, Dept Cardiol, NL-9700 RB Groningen, Netherlands
关键词
chemotherapy; cardiotoxicity; vascular toxicity; long-term; side-effect;
D O I
10.1053/ctrv.2000.0175
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
As a consequence of-the successful use of chemotherapy in the treatment of curable neoplasms such as germ cell tumours and malignant lymphomas, and the increasing application of primary and adjuvant chemotherapy for various tumour types. the number of patients with a prolonged life expectancy after treatment is rising. Attention to long-term side-effects. including cardiovascular toxicity, is therefore of growing importance. In this review we evaluate the literature on long-term cardiovascular toxicity related to chemotherapy in adult patients. Two categories of patient with favourable life expectancy have been reviewed, namely patients cured of metastatic disease by chemotherapy and patients treated with adjuvant chemotherapy. In the first, category. the literature on long-term cardiovascular morbidity in survivors of metastatic testicular cancer and lymphomas is discussed. while in the second category this is done for patients treated with adjuvant chemotherapy for breast and colon cancer As well as the direct toxic effects of chemotherapy on the cardiovascular system. the indirect toxic effects such as chemotherapy-related metabolic changes that may cause cardiovascular morbidity are also discussed. (C) 2000 Harcourt Publishers Ltd.
引用
收藏
页码:429 / 447
页数:19
相关论文
共 202 条
[1]   LONG-TERM SOMATIC SIDE-EFFECTS AND MORBIDITY IN TESTICULAR CANCER-PATIENTS [J].
AASS, N ;
KAASA, S ;
LUND, E ;
KAALHUS, O ;
HEIER, MS ;
FOSSA, SD .
BRITISH JOURNAL OF CANCER, 1990, 61 (01) :151-155
[2]  
ADAMSON IYR, 1974, AM J PATHOL, V77, P185
[3]   BLEOMYCIN AND RAYNAUDS-PHENOMENON [J].
ADOUE, D ;
ARLET, P .
ANNALS OF INTERNAL MEDICINE, 1984, 100 (05) :770-770
[4]  
Airey C L, 1995, Clin Oncol (R Coll Radiol), V7, P135, DOI 10.1016/S0936-6555(05)80819-2
[5]   Safety aspects of pegylated liposomal doxorubicin in patients with cancer [J].
Alberts, DS ;
Garcia, DJ .
DRUGS, 1997, 54 (Suppl 4) :30-35
[6]   MAGNESIUM-DEFICIENCY AND HYPERTENSION - CORRELATION BETWEEN MAGNESIUM-DEFICIENT DIETS AND MICROCIRCULATORY CHANGES INSITU [J].
ALTURA, BM ;
ALTURA, BT ;
GEBREWOLD, A ;
ISING, H ;
GUNTHER, T .
SCIENCE, 1984, 223 (4642) :1315-1317
[7]  
[Anonymous], 1997, J Clin Oncol, V15, P594
[8]  
[Anonymous], 1985, NEW ENGL J MED, V312, P1465
[9]   LATE CARDIAC TOXICITY OF DOXORUBICIN, EPIRUBICIN, AND MITOXANTRONE THERAPY FOR HODGKINS-DISEASE IN ADULTS [J].
AVILES, A ;
AREVILA, N ;
MAQUEO, JCD ;
GOMEZ, T ;
GARCIA, R ;
NAMBO, MJ .
LEUKEMIA & LYMPHOMA, 1993, 11 (3-4) :275-279
[10]   Cardiotoxicity of the antiproliferative compound fluorouracil [J].
Becker, K ;
Erckenbrecht, JF ;
Häussinger, D ;
Frieling, T .
DRUGS, 1999, 57 (04) :475-484